<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03745885</url>
  </required_header>
  <id_info>
    <org_study_id>YN011A</org_study_id>
    <nct_id>NCT03745885</nct_id>
  </id_info>
  <brief_title>A Study of the Efficacy and Safety of Supaglutide in Healthy Participants</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study the Efficacy and Safety of Supaglutide in Chinese Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of
      the investigational drug Supaglutide proposed dosing once (or twice) weekly in Chinese
      healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 4, 2018</start_date>
  <completion_date type="Anticipated">May 30, 2020</completion_date>
  <primary_completion_date type="Actual">December 13, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic：Cmax of Supaglutide</measure>
    <time_frame>baseline and up to 29 days after formal dose</time_frame>
    <description>Maximum Concentration(Cmax) of Supaglutide</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic: Tmax of Supaglutide</measure>
    <time_frame>baseline and up to 29 days after formal dose</time_frame>
    <description>Time to maximum plasma concentration (Tmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic: AUC0-t of Supaglutide</measure>
    <time_frame>baseline and up to 29 days after formal dose</time_frame>
    <description>Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUC0-t)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic: t½ of Supaglutide</measure>
    <time_frame>baseline and up to 29 days after formal dose</time_frame>
    <description>Terminal elimination half-life in plasma (t½)</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>0.15mg Supaglutide or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.15 milligrams (mg) Supaglutide injection or placebo administered once subcutaneously（SC） to healthy participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.375mg Supaglutide or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.375 milligrams (mg) Supaglutide injection or placebo administered once subcutaneously（SC） to healthy participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.75mg Supaglutide or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.75 milligrams (mg) Supaglutide injection or placebo administered once subcutaneously（SC） to healthy participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.5mg Supaglutide or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.5 milligrams (mg) Supaglutide injection or placebo administered once subcutaneously（SC） to healthy participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3.0mg Supaglutide or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3.0 milligrams (mg) Supaglutide injection or placebo administered once subcutaneously（SC） to healthy participants</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Supaglutide injection</intervention_name>
    <description>Administered SC in the Supaglutide arms.</description>
    <arm_group_label>0.15mg Supaglutide or placebo</arm_group_label>
    <arm_group_label>0.375mg Supaglutide or placebo</arm_group_label>
    <arm_group_label>0.75mg Supaglutide or placebo</arm_group_label>
    <arm_group_label>1.5mg Supaglutide or placebo</arm_group_label>
    <arm_group_label>3.0mg Supaglutide or placebo</arm_group_label>
    <other_name>Diabegone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC in the placebo arms and to maintain the blind in the Supaglutide injection arms.</description>
    <arm_group_label>0.15mg Supaglutide or placebo</arm_group_label>
    <arm_group_label>0.375mg Supaglutide or placebo</arm_group_label>
    <arm_group_label>0.75mg Supaglutide or placebo</arm_group_label>
    <arm_group_label>1.5mg Supaglutide or placebo</arm_group_label>
    <arm_group_label>3.0mg Supaglutide or placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy subjects between 18 and 45 years old（inclusive）.

          2. Body mass index（BMI）is between 18 and 28 kg/m2 (inclusive). The weight of male
             subjects should not be less than 50 kg, and female subjects should not be less than 45
             kg.

          3. The female participant with reproductive potential, will be required a negative
             pregnancy test before trial, maintaining non-pregnancy during the whole study period
             and contraception 3 months after formal injection.

          4. Participants must sign the informed consent.

        Exclusion Criteria:

          1. Have a history of allergic reaction or hypersensitivity to the study drugs, or who
             develop allergic reaction.

          2. Have an evidence of Fasting blood-glucose greater than (&gt;) 6.0 mmol/L or less than (&lt;)
             3.9 mmol/L, or hemoglobin A1c (HbA1c) greater than or equal to (&gt;=) 6.5 percent (%);

          3. Have evidence of Sitting Blood ( take a break for five minutes) , systolic pressure
             exceeds the range of 90 to 140 mmHg, or diastolic pressure exceeds the range of 50 to
             90 mmHg, or Heart Rate exceeds the range of 50 bpm to100 bpm (including critical
             value)

          4. Have an evidence of ECG abnormalities including QTc &gt;450 msec or QRS complex &gt;120
             msec. If QT Corrected &gt;450 msec; or QRS &gt;120msec, subject should Repeat the ECG
             measurements twice and use the average of the QTc or QRS values measured to determine
             whether the subjects are eligible.

          5. Have an evidence of physical examination, vital sign, laboratory examination or
             electrocardiographic examination that investigator think can affect this trial;

          6. Have an individual or a family history of thyroid C-cell tumors/ carcinoma or with a
             history of thyroid dysfunction, thyroid hormone abnormalities or thyroid-related
             hormones exceeded the normal range;

          7. Have a history of significant illness or medical disorders, including acute or chronic
             pancreatitis, cardiovascular disease, renal disorder, hematological disease，hepatic or
             gastrointestinal disease, neurological or psychiatric disease, metabolic disorder, or
             other diseases that may affect the absorption, distribution, metabolism or excretion
             of drugs, such as active gastrointestinal ulcers or bleeding, gastrointestinal
             surgery(except appendectomy).

          8. Have a history of major surgery within 4 weeks or major minor surgery during the whole
             study period;

          9. Have a history of smoking or the use of nicotine products or electronic cigarettes,
             abusing alcohol or abusing drug within 3 months;

         10. Have a presence of prescription or non-prescription drugs, including Chinese
             Traditional and Herbal Drugs within 2 weeks; Previous use of glucagon-like peptide-1
             analogue or another intestinal insulin, or any unknown cause of infections.

         11. Have a presence of any food or drink containing caffeine or xanthine within 48 hours
             before administration.

         12. Have a history of a New Chemical Entity clinical study within the previous 3 months.

         13. Have a presence of pregnancy or lactation.

         14. Have a presence of positive hepatitis B surface antigen (HBsAg) or hepatitis C
             antibody (anti-HCV), or human immunodeficiency virus (HIV) antibody, or treponema
             pallidum antibody.

         15. Have a history of blood donation or loss more than 400 ml (including in the frame of a
             clinical study) within 3 months before administration;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 16, 2018</study_first_submitted>
  <study_first_submitted_qc>November 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2018</study_first_posted>
  <last_update_submitted>April 17, 2020</last_update_submitted>
  <last_update_submitted_qc>April 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

